On the public citation graph

Association between use of febuxostat and muscle injury: A disproportionality analysis and meta‐analysis of randomized controlled trials

0 signed · 50 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/archinte.148.7.1553openalex-snapshot
Factors Predictive of Acute Renal Failure in Rhabdomyolysis
inferredcites →https://doi.org/10.1002/acr.24180openalex-snapshot
2020 American College of Rheumatology Guideline for the Management of Gout
inferredcites →https://doi.org/10.1002/art.20935openalex-snapshot
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty‐eight–day, multicenter, phase II, randomized, double‐blind, placebo‐controlled, dose‐response clinical trial examining safety and efficacy in patients with gout
inferredcites →https://doi.org/10.1002/art.24209openalex-snapshot
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28‐week, phase III, randomized, double‐blind, parallel‐group trial
inferredcites →https://doi.org/10.1002/art.39654openalex-snapshot
Impact of Febuxostat on Renal Function in Gout Patients With Moderate‐to‐Severe Renal Impairment
inferredcites →https://doi.org/10.1002/art.39684openalex-snapshot
A Randomized, Double‐Blind, Active‐ and Placebo‐Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout
inferredcites →https://doi.org/10.1002/art.40233openalex-snapshot
Effects of Febuxostat in Early Gout
inferredcites →https://doi.org/10.1002/art.41247openalex-snapshot
2020 American College of Rheumatology Guideline for the Management of Gout
inferredcites →https://doi.org/10.1002/art.41404openalex-snapshot
Prevalence, Incidence, and Years Lived With Disability Due to Gout and Its Attributable Risk Factors for 195 Countries and Territories 1990–2017: A Systematic Analysis of the Global Burden of Disease Study 2017
inferredcites →https://doi.org/10.1002/pds.1001openalex-snapshot
The reporting odds ratio and its advantages over the proportional reporting ratio
inferredcites →https://doi.org/10.1007/s00228-009-0723-7openalex-snapshot
Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report
inferredcites →https://doi.org/10.1007/s00421-013-2622-yopenalex-snapshot
Genetic polymorphisms associated with exertional rhabdomyolysis
inferredcites →https://doi.org/10.1007/s11906-020-01116-3openalex-snapshot
Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection
inferredcites →https://doi.org/10.1007/s40264-014-0180-9openalex-snapshot
Safety Signal Detection: The Relevance of Literature Review
inferredcites →https://doi.org/10.1016/j.ajog.2008.09.873openalex-snapshot
Metaanalysis vs large clinical trials: which should guide our management?
inferredcites →https://doi.org/10.1016/j.freeradbiomed.2010.10.704openalex-snapshot
Mechanism-based therapeutic approaches to rhabdomyolysis-induced renal failure
inferredcites →https://doi.org/10.1016/j.jbspin.2016.10.008openalex-snapshot
Febuxostat-associated eosinophilic polymyositis in marginal zone lymphoma
inferredcites →https://doi.org/10.1016/j.jbspin.2019.01.018openalex-snapshot
Statins, myalgia, and rhabdomyolysis
inferredcites →https://doi.org/10.1016/j.jclinepi.2009.06.005openalex-snapshot
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
inferredcites →https://doi.org/10.1016/j.nmd.2014.05.005openalex-snapshot
Rhabdomyolysis: Review of the literature
inferredcites →https://doi.org/10.1016/s0140-6736(20)32234-0openalex-snapshot
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial
inferredcites →https://doi.org/10.1053/j.ackd.2013.07.001openalex-snapshot
Tumor Lysis Syndrome: New Challenges and Recent Advances
inferredcites →https://doi.org/10.1053/j.ajkd.2018.06.028openalex-snapshot
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial
inferredcites →https://doi.org/10.1056/evidoa2100028openalex-snapshot
Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management
inferredcites →https://doi.org/10.1056/nejmoa050373openalex-snapshot
Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout
inferredcites →https://doi.org/10.1056/nejmoa1710895openalex-snapshot
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
inferredcites →https://doi.org/10.1093/ehjcvp/pvaa144openalex-snapshot
Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study
inferredcites →https://doi.org/10.1097/rhu.0b013e31821d351dopenalex-snapshot
Placebo-Controlled Double-Blind Dose-Response Study of the Non-Purine-Selective Xanthine Oxidase Inhibitor Febuxostat (TMX-67) in Patients With Hyperuricemia (Including Gout Patients) in Japan
inferredcites →https://doi.org/10.1097/rhu.0b013e31821d352fopenalex-snapshot
An Allopurinol-Controlled, Multicenter, Randomized, Open-Label, Parallel Between-Group, Comparative Study of Febuxostat (TMX-67), a Non-Purine-Selective Inhibitor of Xanthine Oxidase, in Patients With Hyperuricemia Including Those With Gout in Japan
inferredcites →https://doi.org/10.1097/rhu.0b013e31821d36deopenalex-snapshot
Placebo-Controlled, Double-Blind Study of the Non-Purine-Selective Xanthine Oxidase Inhibitor Febuxostat (TMX-67) in Patients With Hyperuricemia Including Those With Gout in Japan
inferredcites →https://doi.org/10.1111/jcpt.12144openalex-snapshot
Rhabdomyolysis associated with initiation of febuxostat therapy for hyperuricaemia in a patient with chronic kidney disease
inferredcites →https://doi.org/10.1136/bmj.315.7109.629openalex-snapshot
Bias in meta-analysis detected by a simple, graphical test
inferredcites →https://doi.org/10.1136/bmj.39489.470347.adopenalex-snapshot
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
inferredcites →https://doi.org/10.1161/circulationaha.114.014536openalex-snapshot
Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients
inferredcites →https://doi.org/10.1177/03000605211062770openalex-snapshot
Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial
inferredcites →https://doi.org/10.1186/1471-2318-12-11openalex-snapshot
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
inferredcites →https://doi.org/10.1213/ane.0000000000005096openalex-snapshot
Basic Science of Frailty—Biological Mechanisms of Age-Related Sarcopenia
inferredcites →https://doi.org/10.1371/journal.pmed.1003095openalex-snapshot
Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial
inferredcites →https://doi.org/10.1371/journal.pone.0221504openalex-snapshot
The impact of adoption of a new urate-lowering agent on trends in utilization and cost in practice
inferredcites →https://doi.org/10.2215/cjn.08280816openalex-snapshot
Risk of Febuxostat-Associated Myopathy in Patients with CKD
inferredcites →https://doi.org/10.5694/mja14.01404openalex-snapshot
Febuxostat‐associated rhabdomyolysis in chronic renal failure
inferredcites →https://doi.org/10.7326/0003-4819-151-4-200908180-00135openalex-snapshot
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
inferredcites →https://doi.org/10.7326/m16-0461openalex-snapshot
Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4832604openalex-extracted
Medication -Induced Rhabdomyolysis: A Disproportionality Analysis of the FAERS Data
inferred← citeshttps://doi.org/10.1002/jcph.2369openalex-snapshot
Urate‐Lowering Drugs and Muscle Injury: A Systematic Review and Network Meta‐Analysis
inferred← citeshttps://doi.org/10.1016/j.intimp.2024.112022openalex-snapshot
Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis/pericarditis: A pharmacovigilance study
inferred← citeshttps://doi.org/10.1097/fjc.0000000000001778openalex-snapshot
Muscle Adverse Events Associated With Inclisiran: Data Mining of FAERS Database and Mendelian Randomization Analysis
inferred← citeshttps://doi.org/10.1111/bcpt.70271openalex-snapshot
Using Pharmacovigilance Data for Signal Detection of Drug Interactions for Rosuvastatin
inferred← citeshttps://doi.org/10.29296/25877305-2023-07-11openalex-snapshot
Chronic gouty arthritis and kidney damage: a clinical example
inferred← citeshttps://doi.org/10.7759/cureus.63303openalex-snapshot
Rhabdomyolysis Associated With Febuxostat in a Non-Chronic Kidney Disease (CKD) Patient: Diagnostic and Management Challenges
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.